Factors Associated with the Decision to Decline Chemotherapy in Metastatic Non-Small Cell Lung Cancer

Author:

Jabbal Iktej Singh1ORCID,Sabbagh Saad1ORCID,Itani Mira1ORCID,Dominguez Barbara1ORCID,Mohanna Mohamed1,Henry Valencia2,Liang Hong3,Saravia Diana1,George Tiffany1,Nahleh Zeina1,Alley Evan1,Arteta-Bulos Rafael1

Affiliation:

1. Department of Hematology/Oncology, Maroone Cancer Center, Cleveland Clinic Florida, Weston, FL 33331, USA

2. OMS-II, Edward Via College of Osteopathic Medicine-Carolinas Campus, Spartanburg, SC 29303, USA

3. Department of Clinical Research, Cleveland Clinic Florida, Weston, FL 33331, USA

Abstract

(1) Background: Disparities in cancer treatment and outcomes have long been well-documented in the medical literature. With the eruption of advances in new treatment modalities, the long-existing disparities are now being further uncovered and brought to the attention of the medical community. While social health determinants have previously been linked to treatment disparities in lung cancer, we analyzed data from the National Cancer Database to explore sociodemographic and geographic factors related to accepting or declining physician-recommended chemotherapy. Patients diagnosed with metastatic lung cancer between 2004 and 2016 who declined chemotherapy recommended by their physicians were included in this study. Multivariate logistic regression analysis was performed. Cox Regression and Kaplan-Meier analyses were performed to look for survival characteristics. (2) Results: 316,826 patients with Stage IV lung cancer were identified. Factors related to a higher rate of refusal by patients included older age > 70, female sex, low income, lack of insurance coverage, residency in the New England region, and higher comorbidity. Patients living in areas with lower education were less likely to decline chemotherapy. (3) Conclusion: Further understanding of the factors impacting treatment decisions would be essential to improve the efficacy of care delivery in patients with cancer and reduce reversible causes of disparity.

Funder

Cleveland Clinic Florida’s internal funding

Publisher

MDPI AG

Subject

Cancer Research,Oncology

Reference44 articles.

1. Cancer statistics, 2022;Siegel;CA Cancer J. Clin.,2022

2. Non-Small Cell Lung Cancer: Epidemiology, Screening, Diagnosis, and Treatment;Duma;Mayo. Clin. Proc.,2019

3. Trends in the incidence, treatment, and survival of patients with lung cancer in the last four decades;Lu;Cancer Manag. Res.,2019

4. The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer;Goldstraw;J. Thorac. Oncol.,2016

5. Oncology ASoC (2023, February 04). Lung Cancer—Non Small Cell: Statistics 2021. Available online: https://www.cancer.net/cancer-types/lung-cancer-non-small-cell/statistics#:~:text=For%20people%20with%20localized%20NSCLC,survival%20rate%20is%20about%2035%25.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3